Hutchmed signs $1.3B GSK licensing deal for KRAS-EGFR therapy
Hutchmed announced a licensing and co-development agreement with GSK for HMPL-A830, a novel KRAS-EGFR antibody conjugate, valued at $1.3 billion with milestone and royalty potential. Deal aims to accelerate global development and validate ATTC platform.
A major licensing and co-development deal was announced with GSK for the novel KRAS-EGFR antibody conjugate HMPL-A830, valued at $1.3 billion with significant milestone and royalty potential.
The agreement accelerates global development, validates the ATTC platform, and expands the precision oncolo…